[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chongqing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":311},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,67,90,116,139,162,192,218,238,266,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644745","intensive-vs-standard-blood-pressure-control-in-primary-aldosteronism-100644745",false,"NCT07673445","Intensive vs. Standard Blood Pressure Control in Primary Aldosteronism","Intensive Versus Standard Blood Pressure Control in Patients With Primary Aldosteronism (Intensia-Aldo): A Multi-center, Randomized Controlled Trial","Intensia-Aldo","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for enrollment:\n\n1. A diagnosis of PA meeting the following criteria: an upright plasma aldosterone-to-renin ratio (ARR) ≥20 (pg\u002FmL)\u002F(μIU\u002FmL) or ≥300 (pg\u002FmL)\u002F(ng\u002FmL\u002Fh); and at least one positive confirmatory test: plasma aldosterone ≥110 pg\u002FmL after the captopril challenge test (CCT) or plasma aldosterone ≥80 pg\u002FmL after the seated saline infusion test (SSIT).\n\n   Note: For patients with an upright ARR ratio between 10-20 (pg\u002FmL)\u002F(μIU\u002FmL), the screening result can also be considered positive if they have additional high-risk factors such as adrenal lesions or resistant hypertension. Patients receiving medications that may suppress renin and lead to false-positive results (e.g., β-adrenergic blockers and centrally acting α₂-agonists such as clonidine or α-methyldopa) should discontinue these medications and repeat testing after a 2-week washout period.\n2. Systolic blood pressure of 140-190 mmHg (or currently receiving antihypertensive treatment).\n\n   Notes: (1) Office mean seated blood pressure is defined as the average of three seated blood pressure measurements obtained at any single on-site visit. (2) There is no diastolic blood pressure criterion for inclusion.\n3. Increased risk of cardiovascular disease (one or more of the following):\n\n   * Previous history of clinical CVD (≥ 3 months)\n\n     * Stroke\n     * Myocardial infarction\n     * Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n     * Carotid endarterectomy or carotid stenting\n     * Peripheral artery disease (PAD) with revascularization\n     * Acute coronary syndrome with or without resting ECG change, ECG changes on a graded exercise test, or positive cardiac imaging study\n   * Subclinical CVD within 3 years\n\n     * ≥50% stenosis of a coronary, carotid, or lower extremity artery\n     * Ankle brachial index (ABI) ≤0.90\n     * Chest pain with evidence of myocardial ischemia\n   * 2 or more CVD risk factors\n\n     * Male ≥50 years or female ≥55 years\n     * History of smoking (≥1 cigarette per day in the past 12 months)\n     * Diabetes mellitus\n     * BMI \\>28 kg\u002Fm²\n     * Dyslipidemia despite receiving maximally tolerated statin therapy: LDL cholesterol \\>130 mg\u002FdL (\\>3.36 mmol\u002FL), or HDL cholesterol \\\u003C40 mg\u002FdL (\\\u003C1.03 mmol\u002FL) in males or \\\u003C50 mg\u002FdL (\\\u003C1.29 mmol\u002FL) in females\n     * Family history of premature coronary heart disease (defined as myocardial infarction or coronary revascularization) in a first-degree relative: male relative \\\u003C55 years or female relative \\\u003C65 years\n     * Microalbuminuria (Note: If microalbuminuria is the only criterion, a repeat test is required for confirmation)\n   * Estimated glomerular filtration rate (eGFR) 30-59 ml\u002Fmin\u002F1.73 m²\n\nExclusion Criteria:\n\n1. Patients with PA who are planned to undergo adrenal surgical treatment.\n2. Other clearly diagnosed forms of secondary hypertension (excluding subclinical Cushing's syndrome and obstructive sleep apnea \\[OSA\\]).\n3. Severe hypertension: systolic blood pressure (SBP) ≥190 mmHg or diastolic blood pressure (DBP) ≥110 mmHg.\n4. Diastolic blood pressure \\\u003C60 mmHg (without antihypertensive medication).\n5. Myocardial infarction, unstable angina, stroke, or coronary revascularization (PCI or CABG) within the past 3 months.\n6. Planned coronary revascularization (PCI or CABG) within the next 6 months.\n7. Severe valvular heart disease, or valvular disease likely to require surgical or percutaneous valve replacement during the study period.\n8. Hypertrophic cardiomyopathy (HCM). Definition: A disease characterized by unexplained left ventricular hypertrophy, with a non-dilated ventricular cavity and absence of other cardiac or systemic diseases. Clinically, HCM is usually diagnosed by echocardiography, defined as a maximum left ventricular wall thickness ≥15 mm, or 13-14 mm (considered borderline), particularly in the presence of additional supporting evidence (e.g., a family history of HCM). In elderly patients with left ventricular hypertrophy and a long-standing history of systemic hypertension, a diagnosis of HCM may be established if a definite sarcomeric gene mutation is identified, or if left ventricular wall thickness is markedly \\>25 mm and\u002For there is left ventricular outflow tract obstruction with systolic anterior motion of the mitral valve and mitral valve-septal contact.\n9. NYHA functional class III-IV heart failure or left ventricular ejection fraction \\\u003C35%.\n10. ALT or AST \\>2.5 times the upper limit of normal, or active liver disease.\n11. Dialysis dependence or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m².\n12. Polycystic kidney disease or glomerulonephritis.\n13. Any condition with an expected life expectancy \\\u003C5 years.\n14. Factors likely to affect adherence to the intervention, including:\n\n    * Alcohol abuse or drug abuse within the past 12 months.\n    * History of severe non-adherence to medication or follow-up.\n    * Residence far from the study center or planned relocation within 5 years.\n    * Clinical diagnosis or treatment of dementia, or cognitive impairment preventing adherence to the protocol.\n    * Other medical, psychiatric, or behavioral factors that may interfere with study participation.\n15. Failure to provide written informed consent.\n16. Current participation in another interventional study.\n17. Pregnancy, planned pregnancy, or women of childbearing potential not using effective contraception.","ALL",{"count":19,"type":20},3830,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether an intensive blood pressure control strategy (systolic blood pressure target \\\u003C120 mmHg) is more effective than a standard strategy (systolic blood pressure target \\\u003C140 mmHg) in reducing the risk of cardiovascular events in patients with primary aldosteronism.\n\nThe main question it aims to answer is: Does the intensive blood pressure control strategy reduce the risk of composite cardiovascular events more than the standard strategy in patients with primary aldosteronism? The study employs a randomized design, allocating participants in a 1:1 ratio to either the Intensive Treatment Group or the Standard Treatment Group. Researchers will compare the differences in cardiovascular outcomes and safety profiles between the two groups over a planned follow-up period of 6 to 10 years.\n\nParticipants will:\n\nUndergo randomization and adhere to the assigned blood pressure management protocol.\n\nAttend regular follow-up visits for blood pressure measurement, laboratory tests, questionnaires, etc.\n\nReport any adverse events or changes in health status.",[26],"Primary Aldosteronism",[28,29],"treatment","intensive blood pressure control","NOT_YET_RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":20},"2026-06",{"date":38,"type":20},"2036-12",{"name":40,"class":41},"Chongqing Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100641440","shortwave-intervention-for-diabetic-peripheral-neuropathy-100641440","NCT07625007","Shortwave Intervention for Diabetic Peripheral Neuropathy.","Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)","Inclusion Criteria:\n\n* 1\\. Aged 18-85 years, regardless of gender, with the ability to act independently;\n* 2\\. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation);\n* 3\\. Able to complete the TCSS assessment;\n* 4\\. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form.\n* 5\\. Patients who did not respond to adequate treatment with mecobalamin and other medications.\n\nExclusion Criteria:\n\n* 1\\. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.);\n* 2\\. Hemorrhagic diseases, malignant tumors;\n* 3\\. History of below-knee amputation;\n* 4\\. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker;\n* 5\\. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR \\\u003C 15 ml\u002Fmin\u002F1.73m²), or cognitive impairment preventing cooperation;\n* 6\\. Pregnancy, breastfeeding, or planning pregnancy;\n* 7\\. Participation in other interventional clinical trials within the past 3 months;\n* 8\\. Combined severe psychiatric disorders;\n* 9\\. Other conditions assessed by the investigator that prevent completion of the trial;\n* 10\\. Poor compliance.","18 Years","85 Years",{"count":53,"type":20},202,[23],"This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment group and 20% in the control group, with the superiority margin set at 20%. This study will provide high-quality evidence-based medical evidence for the use of shortwave therapy in diabetic peripheral neuropathy.",[57],"Diabetic Peripheral Neuropathy","RECRUITING","2026-06-16",{"date":61,"type":34},"2026-06-18",{"date":63,"type":20},"2026-05-20",{"date":65,"type":20},"2027-05-20",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":89,"locationsCount":42},"100641528","ultrasound-guided-nerve-hydrodissection-for-diabetic-lower-limb-entrapment-neuropathy-100641528","NCT07625020","Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy","Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial","HUND","Inclusion Criteria:\n\n1. Age 18-85 years, male or female;\n2. Diagnosis of DLLEN meeting the following criteria: ① Clinical diagnosis of DPN (presence of DPN clinical symptoms plus at least one positive physical sign, or absence of symptoms but presence of two or more positive physical signs), with other etiologies excluded; ② Presence of unilateral or bilateral lower limb symptoms suggestive of peripheral nerve entrapment, including hypoesthesia\u002Fparesthesia in a specific nerve distribution area, pain and\u002For motor dysfunction, or a positive Tinel sign at the corresponding site; ③ Physical examination findings such as decreased or absent skin sensation in the corresponding nerve distribution area, reduced or absent strength of ankle dorsiflexion or eversion, metatarsophalangeal joint movement disorder, foot drop, or foot inversion; ④ Electrophysiological study showing slowing or blockade of nerve conduction velocity at a specific site (across a narrowed segment); ⑤ Imaging study (nerve ultrasound) showing compression of the corresponding nerve (cross-sectional area at the entrapment site exceeding the upper limit of the reference range, decreased nerve echogenicity, or swelling of the nerve fascicles). Diagnosis requires fulfillment of ①, ②, and ③, plus either ④ or ⑤;\n3. Inadequate response to adequate treatment with medications such as mecobalamin and α-lipoic acid;\n4. Understanding of the entire study process and voluntary provision of written informed consent.\n\nExclusion Criteria:\n\n1. Presence of another clearly identified etiology assessed by the investigator as the primary cause of the patient's current lower limb neurological symptoms, including but not limited to: cervical or lumbar spine disease (e.g., radicular symptoms or sciatica), lower extremity vascular disease, cerebral infarction, thyroid dysfunction, vitamin B12 deficiency, heavy alcohol use history, recent chemotherapy or radiotherapy, drug toxicity, or other non-diabetic causes of neuropathy (e.g., CIDP, cauda equina syndrome, subacute combined degeneration of the spinal cord, Guillain-Barré syndrome);\n2. Concurrent malignancy, active systemic infection, or immune system disease;\n3. Lower limb edema due to any cause;\n4. Skin breakdown or infection at the treatment site below the knee;\n5. Severe cardiac, hepatic, or renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m², liver transaminases \\>2.5 times the upper limit of normal, or New York Heart Association functional class ≥II);\n6. Cognitive impairment or severe mental illness;\n7. Pregnancy or breastfeeding;\n8. Participation in another interventional clinical trial within the past 3 months;\n9. Poor compliance, assessed as unlikely to complete the study per protocol;\n10. Any other condition assessed by the investigator as making the patient unsuitable to complete the trial.",{"count":76,"type":20},266,[23],"The goal of this clinical trial is to learn if a single session of ultrasound-guided nerve hydrodissection can relieve symptoms of diabetic lower limb entrapment neuropathy, a condition caused by compressed nerves in the leg that leads to numbness, pain, or muscle weakness in people with diabetes. The main questions it aims to answer are whether nerve hydrodissection improves nerve function (measured by the Toronto Clinical Scoring System) one month after treatment, and whether it relieves pain and improves quality of life. Researchers will compare two groups: one will receive the actual nerve hydrodissection (injection of medicine around the compressed nerve), and the other will receive a sham procedure that involves injecting a small amount of fluid under the skin (not around the nerve). Participants will not know which group they are in, and the researchers who measure the results will also not know. Participants will have four in-person visits over about one month, complete questionnaires about their nerve symptoms, pain, and quality of life, undergo nerve ultrasound at the beginning and at follow-up visits (at 1 month after treatment), and receive either the nerve hydrodissection or the sham procedure at the second visit. All participants will continue their regular diabetes and nerve medication during the study.",[57,80],"Entrapment Neuropathy",[82,80,83],"Diabetic peripheral neuropathy","Nerve Hydrodissection","2026-06-15",{"date":86,"type":34},"2026-06-17",{"date":63,"type":20},{"date":65,"type":20},{"name":40,"class":41},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100631655","physiological-study-of-high-peep-in-noninvasive-ventilation-100631655","NCT07503509","Physiological Study of High PEEP in Noninvasive Ventilation","A Physiological Study of High PEEP During Noninvasive Ventilation in Patients With Hypoxemic Respiratory Failure","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. PaCO₂ ≤ 50 mmHg\n3. PaO₂\u002FFiO₂ ≤ 300 mmHg\n4. Use of a noninvasive ventilator with esophageal pressure monitoring capability (e.g., Mindray SV70) -\n\nExclusion Criteria:\n\n1. Respiratory failure caused by heart failure, asthma, or acute exacerbation of chronic obstructive pulmonary disease (COPD) (COPD as a comorbidity may be included)\n2. Pneumothorax\n3. Patients who refuse to participate in this trial -","100 Years",{"count":99,"type":20},50,[23],"To investigate the physiological effects of high positive end-expiratory pressure (PEEP) during noninvasive ventilation in patients with hypoxemic respiratory failure, and to elucidate the mechanisms underlying high PEEP-induced improvement in oxygenation.",[103],"Respiratory Failure With Hypoxia",[105,106,107],"noninvasive ventilation","PEEP","respiratory failure","2026-03-25",{"date":110,"type":34},"2026-03-31",{"date":112,"type":34},"2024-03-26",{"date":114,"type":20},"2026-06-30",{"name":40,"class":41},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":42},"100444592","prediction-of-extubation-failure-a-multicenter-prospective-observational-study-100444592","NCT05069441","Prediction of Extubation Failure: A Multicenter Prospective Observational Study","The First Affiliated Hospital of Chongqing Medical University","Inclusion Criteria:\n\n* Prepared for extubation through spontaneous breathing trial;Oral or nasal endotracheal intubation; be at least 18 years old\n\nExclusion Criteria:\n\n* Extubation without a spontaneous breathing trial ;Reintubation due to secondary surgery; Tracheotomy",{"count":124,"type":20},2604,"OBSERVATIONAL","The investigators intend to collect several variables to predict extubation failure among patients who successfully complete a spontaneous breathing trial, and then develop a scale using simple bedside indicators to predict extubation failure.",[128],"Mechanical Ventilation",[130],"Extubation Failure","2026-03-20",{"date":133,"type":34},"2026-03-23",{"date":135,"type":34},"2021-10-15",{"date":137,"type":20},"2026-12-31",{"name":40,"class":41},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":42},"100615921","high-peep-in-noninvasive-ventilation-patients-with-pneumonia-or-ards-100615921","NCT07298889","High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS","Effect of High Versus Low Positive End-Expiratory Pressure on Intubation-Free Survival in Patients With Pneumonia or ARDS Receiving Noninvasive Ventilation: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18 years\n* PaO2\u002FFiO2 ≤300 mmHg or SpO2\u002FFiO2 ≤315（SpO2 ≤97%)\n* Anticipated NIV duration \\> 12 h\n* Preserved consciousness (GCS≥13)\n\nExclusion Criteria:\n\n* Use of NIV \\> 24 h before randomization\n* Acute-on-chronic respiratory failure\n* Congestive heart failure\n* Use of NIV after extubation (within 48 hours)\n* Contraindications to NIV (e.g., anatomical malformations, recent pulmonary\u002Fesophageal surgery \\[within 7 days\\])\n* Pneumothorax\n* NIV intolerance\n* Refusal to participate\n* Pregnancy\n* Need for emergency intubation",{"count":147,"type":20},706,[23],"Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.",[151,152,153],"Noninvasive Ventilation","Pneumonia","ARDS","2026-01-06",{"date":156,"type":34},"2026-01-07",{"date":158,"type":34},"2026-01-04",{"date":160,"type":20},"2029-12-31",{"name":40,"class":41},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":42},"100514162","association-of-hscar-with-mafld-and-liver-fibrosis-a-cross-sectional-study-100514162","NCT05974904","Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study","Association of High-sensitivity C-reactive Protein to Albumin Ratio with Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: a Cross-sectional Study","Inclusion Criteria:\n\n* Total participants from NHANES 2017-2020\n* Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.\n\n  1. Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol\u002Fmol); (3) fasting plasma glucose ≥ 7.0 mmol\u002FL (126 mg\u002FdL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol\u002FL (200 mg\u002FdL).\n  2. Overweight or obesity: defined as BMI≥25 kg\u002Fm2 in Caucasians or BMI≥23 kg\u002Fm2 in Asians\n  3. If presence of at least two metabolic risk abnormalities:\n\n     * Waist circumference≥102\u002F88 cm in Caucasian men and women (or≥90\u002F80 cm in Asian men and women)\n     * Blood pressure≥130\u002F85 mmHg or specific drug treatment\n     * Plasma triglycerides≥150 mg\u002Fdl (≥1.70 mmol\u002FL) or specific drug treatment\n     * Plasma HDL-cholesterol \\\u003C40 mg\u002Fdl (\\\u003C1.0 mmol\u002FL) for men and \\\u003C50 mg\u002Fdl (\\\u003C1.3 mmol\u002FL) for women or specific drug treatment\n     * Prediabetes (i.e., fasting glucose levels 100 to 125 mg\u002Fdl \\[5.6 to 6.9 mmol\u002FL\\], or 2-hour post-load glucose levels 140 to 199 mg\u002Fdl \\[7.8 to 11.0 mmol\\] or HbA1c 5.7% to 6.4% \\[39 to 47 mmol\u002Fmol\\])\n     * Homeostasis model assessment of insulin resistance score≥2.5\n     * Plasma high-sensitivity C-reactive protein level \\>2 mg\u002FL\n\nExclusion Criteria:\n\n* Liver ultrasound data not available\n* participants without complete clinical data\n* participants under 18 years old\n* participants with cancer.","90 Years",{"count":171,"type":20},7000,"The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).\n\nThe main question\\[s\\] it aims to answer are:\n\n\\[question 1\\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \\[question 2\\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?",[174,175,176],"Metabolic Dysfunction-associated Fatty Liver Disease","Hepatic Steatosis","Liver Fibrosis",[178,179,180,181,182,183],"high-sensitivity C-reactive protein to albumin ratio","metabolic dysfunction-associated fatty liver disease","National Health and Nutrition Examination Survey","control attenuation parameter","liver stiffness measurement","inflammation","2025-02-10",{"date":186,"type":34},"2025-02-12",{"date":188,"type":34},"2023-07-18",{"date":190,"type":20},"2026-12-28",{"name":40,"class":41},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":199,"sex":17,"minAge":50,"maxAge":169,"enrollmentInfo":200,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":42},"100557670","positive-association-of-us-fli-with-the-severity-of-cad-100557670","NCT06541132","Positive Association of US-FLI With the Severity of CAD","Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study\n\nExclusion Criteria:\n\n* Incomplete clinical data\n* previous coronary stent implantation\n* no abdominal ultrasound examination\n* poor ultrasound image quality\n* congenital heart disease\n* tumor\n* thyroid diseases and infectious diseases",true,{"count":201,"type":20},190,"As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.",[204,174,205,206],"Coronary Artery Disease of Significant Bypass Graft","SYNTAX Score","Ultrasonography",[208,174,209,206],"Coronary Artery Disease","SYNTAX score","2024-08-19",{"date":212,"type":34},"2024-08-21",{"date":214,"type":34},"2022-07-01",{"date":216,"type":20},"2025-04-28",{"name":40,"class":41},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100559001","multimodal-prognostic-system-for-heart-failure-a-multi-center-study-100559001","NCT06558448","Multimodal Prognostic System for Heart Failure: A Multi-Center Study","Developing a Prognostic Warning System for Heart Failure Based on Multimodal Clinical Data: a Multi-center Retrospective Study","Inclusion Criteria:\n\nAge Requirement: We plan to include adult patients aged 18 and above to ensure the study covers a broad spectrum of the adult heart failure patient population.\n\nDiagnostic Criteria: Patients should have a discharge diagnosis of heart failure according to the guidelines for heart failure diagnosis and treatment.\n\nTime Frame: The discharge time of patients should be between January 2011 and December 2024 to collect and analyze data from the past several years.\n\nData Integrity: There is a preference for including medical records with high data integrity, but the specific criteria may be adjusted according to the actual situation of the dataset.\n\nExclusion Criteria:\n\nData Missing: Patients with more than 30% missing data in their medical records may be considered for exclusion to ensure the accuracy and reliability of the analysis.\n\nDiagnostic Inconsistency: Patients with unclear diagnoses or potential for confusion with other diseases may be excluded to ensure the specificity of the study.\n\nNon-standard Treatment: Patients who have not received treatment according to the established treatment protocol may be excluded to reduce the impact of treatment variability on the study results.",{"count":226,"type":20},100000,"This study is a multicenter retrospective research aimed at developing a heart failure prognosis warning system based on multimodal clinical data to improve the diagnosis and treatment of heart failure.\n\nThis study aims to address the following main questions:\n\n1. What are the clinical characteristics and current treatment status of heart failure patients?\n2. What factors influence the onset of heart failure and the prognosis of patients?\n3. How can real-world big data be utilized to construct an accurate heart failure prognosis assessment model?\n4. How can this prognosis assessment model help improve the therapeutic effects and quality of life for heart failure patients?",[229],"Heart Failure","2024-08-14",{"date":232,"type":34},"2024-08-16",{"date":234,"type":20},"2024-08",{"date":236,"type":20},"2024-12",{"name":40,"class":41},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":199,"sex":17,"minAge":50,"maxAge":246,"enrollmentInfo":247,"targetDuration":249,"studyType":125,"phases":4,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":42},"100338930","chongqing-diabetes-registry-study-100338930","NCT03692884","Chongqing Diabetes Registry Study","Chongqing Diabetes and Its Chronic Complications Registry Study","CDR","Inclusion Criteria:\n\n1. Diagnosis of diabetes mellitus（based on the 1999 WHO diagnostic cretirial）;\n2. Age younger than 75 years old, gender is not limited;\n3. Voluntary to sign on the informed consent.\n\nExclusion Criteria:\n\n1. pregnant or breast-feeding women;\n2. Patients with chronic disease requiring long-term glucocorticoid therapy;\n3. Patients with severe infection (except for diabetic foot) or immune dysfunction.","75 Years",{"count":248,"type":20},5000,"10 Years","To investigate the risk factors and biomarkers of the microvascular disease，macrovascular disease and neuropathy in patients with diabetes.",[252],"Diabetes Mellitus",[254,255,256,257],"diabetes mellitus","risk factors","biomarkers","chronic diabetes complications","2023-09-04",{"date":260,"type":34},"2023-09-06",{"date":262,"type":34},"2018-07-01",{"date":264,"type":20},"2030-07-01",{"name":40,"class":41},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":42},"100302988","chongqing-primary-aldosteronism-study-100302988","NCT03224312","Chongqing Primary Aldosteronism Study","Inclusion Criteria:\n\n1. hypertensive patients who completed ARR screening and necessary further tests;\n2. Voluntary to sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with severe cardiac, hepatic or renal dysfunction;\n2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.","80 Years",{"count":274,"type":20},1500,"We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.",[26],[278,279,280],"Primary aldosteronism","cardiovascular events","cerebrovascular events",{"date":260,"type":34},{"date":283,"type":34},"2016-10-01",{"date":285,"type":20},"2028-12-31",{"name":40,"class":41},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100496415","cohort-study-of-adrenogenic-autonomic-cortisol-secretion-100496415","NCT05743933","Cohort Study of Adrenogenic Autonomic Cortisol Secretion","Inclusion Criteria:\n\n* CT examination revealed adrenal nodules (maximum diameter ≥10mm);\n* Serum cortisol \\> 50nmol\u002FL after 1mg dexamethasone inhibition test (1mg-DST).\n\nExclusion Criteria:\n\n* Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma\u002Fparaganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function.\n* Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy.\n* Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis.\n* Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.",{"count":294,"type":20},200,"To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.",[297,298,299],"Diagnosis","Treatment","Adrenogenic Autonomic Cortisol Secretion",[301,302,299],"Diagnosis and differential diagnosis","Treatment and prognosis","2023-02-16",{"date":305,"type":34},"2023-02-24",{"date":307,"type":20},"2023-02-17",{"date":309,"type":20},"2033-02-15",{"name":40,"class":41},""]